The small molecule KIRA8 disrupts IRE1α-dependent growth of multiple myeloma cells in mice, and it has greater efficacy in combination with the proteasome inhibitor bortezomib or the immunomodulatory agent lenalidomide [106]. This evidence concerns the gene ERN1 and plasma cell myeloma.